Material Agreement - Form 8-K

Item 1.01. Entry into a Material Definitive Agreement.

As previously disclosed, on April 2, 2020, Akebia Therapeutics, Inc. (the "Company") entered into a Supply Agreement with STA Pharmaceutical Hong Kong Limited, a Hong Kong corporation ("STA"), as amended on April 15, 2021 (as amended, the "Supply Agreement"), under which STA manufactures vadadustat drug substance ("Product") for the Company's commercial purposes.

On April 15, 2024, the Company and STA entered into Amendment #2 to the Supply Agreement (the "Amendment"). Pursuant to the Amendment, the term of the Supply Agreement is extended for an additional five (5) years and expires on April 2, 2029. In addition, the Amendment amends the volume-based pricing structure under the Supply Agreement.

The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the Amendment, a copy of which the Company expects to file as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending June 30, 2024.